These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 14750752)
41. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vila-Corcoles A; Salsench E; Rodriguez-Blanco T; Ochoa-Gondar O; de Diego C; Valdivieso A; Hospital I; Gomez-Bertomeu F; Raga X Vaccine; 2009 Mar; 27(10):1504-10. PubMed ID: 19171174 [TBL] [Abstract][Full Text] [Related]
42. Pneumococcal vaccination process improvement in an acute care setting. Yancey AM; Jundt AB; Nelson KJ Qual Saf Health Care; 2010 Dec; 19(6):e61. PubMed ID: 20798068 [TBL] [Abstract][Full Text] [Related]
44. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine--United States, 1997-2006. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2009 Jan; 58(1):1-4. PubMed ID: 19145219 [TBL] [Abstract][Full Text] [Related]
45. Evaluation of pneumococcal vaccination rates after vaccine protocol changes and nurse education in a tertiary care teaching hospital. Smith JG; Metzger NL J Manag Care Pharm; 2011 Nov; 17(9):701-8. PubMed ID: 22050395 [TBL] [Abstract][Full Text] [Related]
46. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Albrich WC; Baughman W; Schmotzer B; Farley MM Clin Infect Dis; 2007 Jun; 44(12):1569-76. PubMed ID: 17516400 [TBL] [Abstract][Full Text] [Related]
47. Comparison of hospitalists and nonhospitalists regarding core measures of pneumonia care. Rifkin WD; Burger A; Holmboe ES; Sturdevant B Am J Manag Care; 2007 Mar; 13(3):129-32. PubMed ID: 17335356 [TBL] [Abstract][Full Text] [Related]
48. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003. Greene CM; Kyaw MH; Ray SM; Schaffner W; Lynfield R; Barrett NL; Long C; Gershman K; Pilishvili T; Roberson A; Zell ER; Whitney CG; Bennett NM; Clin Infect Dis; 2006 Jul; 43(2):141-50. PubMed ID: 16779739 [TBL] [Abstract][Full Text] [Related]
49. Reducing medical service utilization by encouraging vaccines: randomized controlled trial. Berg GD; Thomas E; Silverstein S; Neel CL; Mireles M Am J Prev Med; 2004 Nov; 27(4):284-8. PubMed ID: 15488357 [TBL] [Abstract][Full Text] [Related]
50. Impact of prior pneumococcal vaccination on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal disease. Imaz A; Falcó V; Peñaranda M; Jordano Q; Martínez X; Nadal C; Curran A; Planes AM; Dalmau D; Ribera E; Riera M; Ruiz de Gopegui E; Pahissa A HIV Med; 2009 Jul; 10(6):356-63. PubMed ID: 19490180 [TBL] [Abstract][Full Text] [Related]
51. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program. Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662 [TBL] [Abstract][Full Text] [Related]
52. Influenza and pneumococcal vaccination in older veterans: results from the behavioral risk factor surveillance system. Chi RC; Reiber GE; Neuzil KM J Am Geriatr Soc; 2006 Feb; 54(2):217-23. PubMed ID: 16460371 [TBL] [Abstract][Full Text] [Related]
53. Changing practices in the use of pneumococcal vaccine. Latessa RA; Cummings DM; Lilley SH; Morrissey SL Fam Med; 2000 Mar; 32(3):196-200. PubMed ID: 10726221 [TBL] [Abstract][Full Text] [Related]
54. Clinical effectiveness of pneumococcal polysaccharide vaccine in men: California Men's Health Study. Hechter RC; Chao C; Jacobsen SJ; Slezak JM; Quinn VP; Van Den Eeden SK; Tseng HF Vaccine; 2012 Aug; 30(38):5625-30. PubMed ID: 22789510 [TBL] [Abstract][Full Text] [Related]
55. Utilization of pneumococcal vaccine in a family practice residency. Brownlee HJ; Brown DL; D'Angelo RJ J Fam Pract; 1982 Dec; 15(6):1111-4. PubMed ID: 7142929 [TBL] [Abstract][Full Text] [Related]
56. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma. Landgren O; Björkholm M; Konradsen HB; Söderqvist M; Nilsson B; Gustavsson A; Axdorph U; Kalin M; Grimfors G J Intern Med; 2004 Jun; 255(6):664-73. PubMed ID: 15147530 [TBL] [Abstract][Full Text] [Related]
58. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Byington CL; Korgenski K; Daly J; Ampofo K; Pavia A; Mason EO Pediatr Infect Dis J; 2006 Mar; 25(3):250-4. PubMed ID: 16511389 [TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Melegaro A; Edmunds WJ Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710 [TBL] [Abstract][Full Text] [Related]
60. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Zhou F; Kyaw MH; Shefer A; Winston CA; Nuorti JP Arch Pediatr Adolesc Med; 2007 Dec; 161(12):1162-8. PubMed ID: 18056561 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]